# Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

> **NCT06732245** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Biomed Industries, Inc.** · enrollment: 224 (estimated)

## Conditions studied

- Obesity and Overweight

## Interventions

- **DRUG:** NA-931
- **DRUG:** Tirzepatide
- **DRUG:** Tirzepatide
- **DRUG:** NA-931
- **DRUG:** NA-931
- **DRUG:** NA-931
- **DRUG:** NA-931 150 mg + no Tirzepatide
- **DRUG:** NA-931
- **DRUG:** NA-931

## Key facts

- **NCT ID:** NCT06732245
- **Lead sponsor:** Biomed Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2027-08-15
- **Final completion:** 2027-12-15
- **Target enrollment:** 224 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732245, "Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06732245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*